MedTrace Logo

Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients

NCT07618936 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-06-01

No results posted yet for this study

Summary

To evaluate the potential usefulness of 68Ga/18F-PD-L1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PD-L1-related disease patients

Conditions

  • PD-L1 Gene Mutation
  • PD-L1 Gene Amplification
  • PD-L1-related Disease
  • Positron Emission Tomography

Interventions

DIAGNOSTIC_TEST

Single Group Assignment

Each subject receive a single intravenous injection of 68Ga/18F-DMP10 or other PDL1 tracers, and undergo PET/CT imaging within the specificed time.

Sponsors & Collaborators

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Tianjin Medical University

    lead OTHER

Principal Investigators

  • Haonan Yu, MD · Tianjin Medical University General Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2031-06-01
Completion
2031-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07618936 on ClinicalTrials.gov